CSL

From developing treatments that save and improve lives to developing vaccines that protect them, we are a global presence. Daring and caring and never stopping in our pursuit, we know every frontier conquered leads to a new range to be climbed. For us there are no boundaries, only moving forward. Always. We are CSL and we are driven by our promise.

https://www.csl.com/

Close
CSL

Featured
Critical Medicines Act: Ensuring Steady Supply of Plasma-Derived Therapies Partner Content
Critical Medicines Act: Ensuring Steady Supply of Plasma-Derived Therapies
29 Oct Member States
by Irene de Cara Torres
The Critical Medicines Act (CMA) must deliver crisp, coordinated action at EU level, paired with national policies that boost plasma donations, streamline medicine distribution, and safeguard competitiveness. Only by aligning resilience with agility and economic viability can Europe secure long-term access to plasma-derived therapies for patients who depend on them
Articles
The EU's Role in Advancing Access to Gene Therapy for patients Partner Content
05 May
The EU's Role in Advancing Access to Gene Therapy for patients
In this mandate, EU policy-makers have a crucial opportunity to leverage this moment of change and expand access to Advanced therapy medicinal products
A new mandate to champion Rare Diseases: enhancing diagnosis and care for HAE patients in Europe Partner Content
02 Dec 24 EU Institutions
A new mandate to champion Rare Diseases: enhancing diagnosis and care for HAE patients in Europe
A recent debate, sponsored by CSL Behring and hosted by MEPs Andriukaitis and Bosse, brought together hereditary angioedema experts, advocates, and policymakers to advocate for stronger EU action on diagnosis, care, and innovation in rare diseases.
Paving the way for another decade of progress in hemophilia care through EU policy Partner Content
19 Apr 23
Paving the way for another decade of progress in hemophilia care through EU policy
On World Hemophilia Day, the hemophilia community sits together to reflect on progress to date in the care of patients with bleeding disorders, whilst pointing that challenges remain and several EU policy opportunities could be game changers to address these.